Acute Renal Failure
Conditions
Keywords
erythropoietin
Brief summary
Pilot study aiming to assess the effect of two doses of rhu EPO on urine NGAL concentration and on serum cystatin C and creatinine levels in critically ill patients at risk of ARF.
Detailed description
Research plan Open-label randomized trial Twelve months duration trial Setting: Medical and Surgical Intensive Care Unit of the University Hospitals of Geneva Start of trial: Mid-May 2008 Patients randomly allocated to 2 treatment groups (20 patients per group), or a control group (40 patients): * Group 1: control group (40 patients) * Group 2 : 20000 IU rhu Epo (20 patients) administered by the i.v. route * Group 3 : 40000 IU rhu Epo (20 patients) administered by the i.v. route 3.2. Trial design Day 0 Consent form signed Patients randomly allocated to control or treatment groups (20000 and 40000 IU) Serum Cystatin C determination Serum Creatinine determination Urinary NGAL determination Administration of intravenous rhu Epo on Day 0 or no Epo (control group) Day 2 At 48 hr after rhu EPO injection, samples will be taken for * Serum Cystatin C determination * Serum Creatinine determination * Urinary NGAL determination Day 4 At 96 hr after rhu EPO injection, samples will be taken for * Serum Cystatin C determination * Serum Creatinine determination * Urinary NGAL determination Stopping rules The trial for an individual subject, parts of the trial or the entire trial will be stopped when: * at Day 4 for an individual subject * after enrollment of 80 patients Treatment The treatment will consist of intravenous (i.v.) injections of recombinant human erythropoietin (r-hu-EPO). The trial medication will be provided by JANSSEN-CILAG AG. The brand name is EPREX® which is epoietinum-alpha in sterile buffered solution for i.v. or s.c. injection. Patient group 1 will not receive EPO treatment. Patient group 2 will receive 20'000 U of rhu EPO and patient group 3 will receive 40'000 U of rhu EPO (i.v. route).
Interventions
DRUGepoetinum
Administration of intravenous rhu Epo on Day 0 20000 IU rhu Epo (20 patients) administered by the i.v. route 40000 IU rhu Epo (20 patients) administered by the i.v. route
Sponsors
University Hospital, Geneva
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients at risks for acute tubular necrosis (patients with mechanical ventilation, patients with sepsis, in the post-operative state, with hemodynamic impairment or with previous chronic renal failure. * Consent form signed
Exclusion criteria
* Patients with malignant hypertension * Patients with systolic BP \> 150 mmHg at enrollment * Patients with Hb level \> 120g/L * Patients with acute coronaropathy * Pregnancy * Patients with urine output \< 600 ml/12 h
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| mean change (%) from baseline in urinary NGAL concentration at 96 hr after rhu EPO injection | 4 days |
Secondary
| Measure | Time frame |
|---|---|
| mean change (%) from baseline in serum Cystatin C concentration at 96 hr after rhu EPO injection | 4 days |
Countries
Switzerland
Outcome results
None listed